Soliris (eculizumab), given as a treatment or as a preventive measure, reduces disease relapse and kidney transplant loss in…
Articles by Patricia Inácio, PhD
Atypical hemolytic uremic syndrome (aHUS) can co-exist with severe combined immunodeficiency (SCID), a rare genetic disorder characterized by a…
Treatment with Soliris (eculizumab) may be discontinued with close monitoring in people with atypical hemolytic uremic syndrome (aHUS)…
Soliris (eculizumab) was shown to effectively treat atypical hemolytic uremic syndrome (aHUS) triggered by COVID-19 in a patient…
Infection with SARS-CoV-2, the virus that causes COVID-19, may trigger first clinical symptoms or relapse of atypical hemolytic uremic…
Family members of people with atypical hemolytic uremic syndrome (aHUS) who carry mutations in complement genes may be at a…
A 6-month-old girl who was diagnosed with cystic fibrosis (CF) went into kidney failure due to atypical hemolytic…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will…
Treatment with Soliris (eculizumab) successfully prevented the recurrence of atypical hemolytic uremic syndrome (aHUS) in a 64-year-old woman…
Adults with atypical hemolytic uremic syndrome (aHUS) continue to show improvements in kidney function, blood parameters, and quality of…